Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Rakhi Naik MD, MHS

Rakhi Naik MD, MHS

Associate Director for Hematology, Hematology/Oncology Fellowship Program; Associate Professor of Medicine, Hematology, Johns Hopkins Medicine, Baltimore, Maryland

Dr. Naik graduated from Duke University with a degree in Biomedical and Electrical Engineering and received her MD from Cornell Medical School. She also holds a Masters in Health Sciences (MHS) from the Johns Hopkins Bloomberg School of Public Health. Dr. Naik has been at Hopkins since 2006, serving as Osler residency housestaff, hematology fellow, and Assistant Chief of Service (Chief Resident) prior to being recruited to faculty as an Assistant Professor in May 2013. She currently serves as the Associate Director for Hematology for the Hematology-Oncology Fellowship Program and is an Associate Professor of Medicine at Johns Hopkins Medicine.

Dr. Naik’s primary research involves the genetic epidemiology of sickle hemoglobin disorders, with the goal of informing genetic counseling, screening and treatment guidelines. She is currently involved in several large-scale epidemiologic efforts using National Heart, Lung, and Blood Institute (NHLBI) population study cohorts to define clinical complications of sickle cell trait, including venous thromboembolism, renal disease, cardiovascular disease, and stroke.

Dr. Naik serves on the American Society of Hematology (ASH) Committee on Training and is a member of the ASH Recruitment and Retention Working Group, which aims to increase the recruitment of trainees into benign hematology.

Recent Contributions to PracticeUpdate:

  1. Prevalence of VTE in Patients With Severe Novel Coronavirus Pneumonia
  2. COVID-19: Through a Hematologic Filter
  3. tPA for COVID-19–Associated ARDS
  4. D-Dimer Is Associated With Severity of COVID-19
  5. ASH 2019 Guidelines for Sickle Cell Disease: Cardiopulmonary and Kidney Disease
  6. Trends and Factors Affecting the US Adult Hematology Workforce
  7. 2019 Top Stories in Benign Hematology: Novel Drugs in Sickle Cell Disease
  8. Treatment of Post-Transfusion Hyperhemolysis Syndrome in Sickle Cell Disease With Tocilizumab
  9. Real-World Experience With Low-Dose DOACs After Unprovoked Venous Thromboembolism
  10. Sickle Cell Trait and Renal Disease Among African American US Army Soldiers

Recently Updated